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Abstract. 
 
The chemokines monocyte chemoattractant 
protein-1 (MCP-1) and macrophage inﬂammatory pro-
tein-1
 
a
 
 (MIP-1
 
a
 
) aid in directing leukocytes to speciﬁc 
locales within the brain and spinal cord during central 
nervous system inﬂammation. However, it remains un-
clear how these chemokines exert their actions across a 
vascular barrier, raising speculation that interaction 
with endothelial cells might be required. Therefore, ex-
periments were performed to determine whether bind-
ing domains for these chemokines exist along the outer 
surface of brain microvessels, a feature that could po-
tentially relay chemokine signals from brain to blood. 
Using a biotinylated chemokine binding assay with con-
focal microscopy and three-dimensional image recon-
struction, spatially resolved binding sites for MCP-1 
and MIP-
 
a
 
 around human brain microvessels were re-
vealed for the ﬁrst time. Binding of labeled MCP-1 and 
MIP-1
 
a
 
 could be inhibited by unlabeled homologous 
but not heterologous chemokine, and was independent 
of the presence of heparan sulfate, laminin, or collagen 
in the subendothelial matrix. This is the ﬁrst evidence of 
speciﬁc and separate binding domains for MCP-1 and 
MIP-1
 
a
 
 on the parenchymal surface of microvessels, 
and highlights the prospect that speciﬁc interactions of 
chemokines with microvascular elements inﬂuence the 
extent and course of central nervous system inﬂamma-
tion.
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HEMOKINES
 
 have garnered considerable attention
as critical mediators of inflammation (2, 3, 19).
Two chemokines thought to be of particular signif-
icance to central nervous system (CNS)
 
1
 
 inflammation
that accompanies autoimmune, demyelinating disease are
monocyte chemoattractant protein-1 (MCP-1) and macro-
phage inflammatory protein-1
 
a
 
 (MIP-1
 
a
 
; reviewed in 21,
28, 37). Both direct the chemotaxis of monocytes and lym-
phocytes along concentration gradients in vitro (2, 3, 19)
and are synthesized by astrocytes (16, 20, 23) and microg-
lia (14, 24) within the brain parenchyma. Since both these
glial cells extend processes that contact the abluminal sur-
face of brain microvessels (1, 22, 48), it has been conjec-
tured that glial-derived chemokines guide circulating leu-
kocytes through endothelial junctions into the underlying
brain tissue, as depicted in recent reviews (26, 34). Consis-
tent with this interpretation is the observation that MCP-1
expression by perivascular astrocytes correlates tempo-
rally and spatially with the appearance of perivascular in-
filtrates of antigen-independent mononuclear leukocytes
in an animal model of CNS inflammatory disease (12, 13).
Despite the mounting evidence for chemokine involve-
ment in leukocyte extravasation from both CNS and pe-
ripheral vascular beds, a fundamental question remains
unresolved: How do chemokines attract circulating leuko-
cytes from which they are physically separated by a vascu-
lar barrier? This process is particularly hard to envisage in
the CNS, where diffusion of chemokines from parenchy-
mal sites to the vascular lumen would likely be restricted
by the high-resistance tight junctions that characterize the
endothelial cells forming the blood-brain barrier (5).
One hypothesis to explain chemokine action within the
CNS is that chemokine signals are relayed across brain mi-
crovessels through specific interactions with endothelial
cells and/or the subendothelial extracellular matrix. For
example, chemokines might be transported across brain
microvascular endothelium through a transcellular path-
way, as has been postulated recently to occur in dermal
microvessels (29). A requirement for such a mechanism
would be the expression of chemokine binding sites along
the abluminal microvessel surface, that facing the brain
parenchyma. To date, the presence of such binding sites
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1. 
 
Abbreviations used in this paper:
 
 CNS, central nervous system; DARC,
Duffy antigen receptor for chemokines; GAG, glycosaminoglycan; MCP-1,
monocyte chemoattractant protein-1; MIP-1
 
a
 
, macrophage inflammatory
protein-1
 
a
 
; PBM, peripheral blood monocytes; rh, recombinant human. 
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has not been explored in the CNS. Moreover, though ad-
herence of chemokines to peripheral vasculature endothe-
lial cells in culture and tissue sections has been indicated
by radiolabeled binding studies (17, 25, 29, 38, 40, 41), this
has reflected attachment to the apical or luminal endothe-
lial surfaces only. No visual depiction of perivascular
chemokine binding along the parenchymal face of intact
microvessels has been confirmed in any organ system.
As greater understanding of chemokine–vascular inter-
actions should yield important clues to the pathogenesis of
inflammatory disease, the objective of this study was to vi-
sualize and characterize MCP-1 and MIP-1
 
a
 
 binding to
the surface of microvessels freshly isolated from human
brain. To accomplish this, high resolution confocal micros-
copy and three-dimensional image reconstruction were
performed, for the first time, to reveal the perivascular
binding of these chemokines, and to delineate the cellular
and molecular binding domains. Results indicate that
there are specific and separate binding sites for both MCP-1
and MIP-1
 
a
 
 along the abluminal surface of brain mi-
crovessels. Furthermore, these sites do not appear to be
coincident with perivascular macrophages or several ma-
jor components of the peripheral subendothelial matrix,
highlighting the prospect that may be associated with en-
dothelial cells and/or a tightly apposed subendothelial ele-
ment. The physiologic and pathophysiologic significance
of these chemokine binding sites is discussed.
 
Materials and Methods
 
Preparation of Microvessels
 
Human brain microvessels were derived from cortical tissue acquired
from both temporal lobe biopsies and autopsies. Biopsies were obtained
from patients undergoing surgery for the treatment of intractable seizures
at the Yale-New Haven Hospital, and were resected from areas outside
the epileptic foci. Autopsy tissue was acquired from the following sources:
University of Miami and University of Maryland Brain and Tissue Banks
for Developmental Disorders (through NICHC contracts NO1-HD-3-3199
and NO1-HD-1-3138, respectively), Harvard Brain Tissue Resource Cen-
ter Bank (through PHS grant MH/NS 31862) and National Disease Re-
search Interchange (Philadelphia, PA). Final diagnoses included respira-
tory distress and polytrauma, with no evidence of neurologic disease.
Microvessels were prepared by a modification of a previously described
method for the isolation of rat brain microvessels (10). In this case, en-
riched fractions of microvessels obtained by centrifugation through dex-
tran were further purified by isopycnic sedimentation through Percoll (4).
This method yielded a population of microvascular segments that retained
their basement membranes.
 
Binding Experiments
 
Purified microvessels were reacted with either biotinylated recombinant
human (rh)MCP-1 or biotinylated rhMIP-1
 
a
 
 (R&D Systems Inc.), and
subsequently with fluorescein-avidin according to the manufacturer’s di-
rections. All reactions were carried out at 4
 
8
 
C or room temperature to
lessen possible cellular uptake of chemokines or antibodies. For negative
controls, reactions were performed in the presence of anti–human MCP-1
and MIP-1
 
a
 
 antibodies, or included the irrelevant biotinylated protein
soybean trypsin inhibitor (R&D Systems Inc.). As positive controls, pe-
ripheral blood monocytes (PBM), which contain receptors for both MCP-1
and MIP-1
 
a
 
 (2, 3, 19, 35), were subjected to the identical conditions. Com-
petition studies using a single chemokine were performed with constant
concentrations of either biotinylated rhMCP-1 or rhMIP-1
 
a
 
 in the pres-
ence of increasing concentrations of unlabeled, homologous ligand
(rhMCP-1 or rhMIP-1
 
a
 
; both from PeproTech Inc.). Cross-competition
studies between the two chemokines were conducted using a single con-
centration of either biotinylated rhMCP-1 or rhMIP-1
 
a
 
 in the presence of
increasing concentrations of unlabeled, heterologous ligand. Relative
amounts of biotinylated MCP-1 and MIP-1
 
a
 
 bound to microvessels were
quantified using a Zeiss LSM 410 confocal microscope equipped with an
argon-krypton laser (with emission at 488 and 568 nm). Microvessels were
observed with an Achromat 40
 
3
 
/1.3 NA, oil objective, under constant
conditions of aperture, pin-hole, brightness, and contrast. Images (512 
 
3
 
512 pixels) were obtained and processed using Adobe Photoshop 3.0 soft-
ware (Adobe Systems Inc.). To quantify the extent of labeled chemokine
binding, values of mean pixel intensity were recorded from a total of 80
randomly chosen areas (192 pixels each) of microvessels from at least 10
samples. In analogous fashion, mean pixel intensities were also obtained
from microvessels incubated with biotinylated soybean trypsin inhibitor.
The average of the pixel values obtained from this negative control was
then subtracted from each of the 80 pixel intensities obtained from all the
different chemokine binding conditions so as to remove the contribution
of background noise. Corrected pixel intensities were then averaged, with
the resulting value representing the relative degree of specific chemokine
binding along microvessels. 
 
K
 
d 
 
and Hill coefficient (
 
n
 
) values were deter-
mined using Sigma Plot software (Jandel Inc.) and using the following
equation: 
 
b
 
 
 
5
 
 (
 
b
 
max
 
 
 
?
 
 
 
x
 
n
 
)/(
 
K
 
d
 
n
 
 
 
1
 
 
 
x
 
n
 
), where b is indicated by pixel intensity
values.
 
Combined Chemokine
Localization/Immunofluorescence
 
After reacting isolated microvessels with biotinylated chemokines and flu-
orescein-avidin, as described above, or for the specific detection of
chemokine receptors, microvessels were fixed in 4% (wt/vol) paraformal-
dehyde and seeded onto poly-
 
L
 
-lysine–coated glass coverslips. After
blocking nonspecific binding by incubation with PBS containing 5% (vol/
vol) normal goat serum (GIBCO BRL), 1% (wt/vol) BSA (Sigma Chemi-
cal Co.), and 0.5% (vol/vol) Tween (Sigma Chemical Co.), microvessels
were reacted with the different primary antibodies (monoclonal antilami-
nin [clone LAM-89, Sigma Chemical Co.], monoclonal anti–Factor VIII
[clone F8/86, DAKO], monoclonal anti-CD68 [clone EBM11, DAKO],
anti–collagen type IV collagen [Sigma Chemical Co.], and anti–heparan
sulfate proteoglycan [Upstate Biotechnology]), and then exposed to
rhodamine-conjugated goat anti–mouse antibody (Boehringer Mannheim
Biochemicals). Monoclonal antibodies to chemokine receptors CCR1,
CCR2, and CCR5 were all purchased from R&D Systems Inc., and sam-
ples reacted with these antibodies were subsequently visualized with fluo-
rescein-conjugated goat anti–mouse antibody (Boehringer Mannheim
Biochemicals). Negative control samples were processed similarly, except
for the exclusion of primary antibody, while isotype control samples used
similar Ig isotype, irrelevant antibody as a primary source. All samples
were viewed with an Olympus IX70 inverted microscope (40
 
3
 
 objective)
to obtain simple, two-dimensional images, and a Zeiss LSM 410 confocal
microscope (40
 
3
 
/1.3 oil objective) to acquire three-dimensional images.
The latter were generated by taking a z-series of 1-
 
m
 
m-thick optical sec-
tions, usually 20–30, throughout the sample, and then reconstructing and
editing the images using the three-dimensional reconstruction program
VoxelView (Vital Images, Inc.).
 
Heparinase I Digestion
 
Freshly purified brain microvessels were incubated with type I heparinase
(Sigma Chemical Co.; 50 U/ml in DME/F-12; GIBCO BRL) for 1 h at
37
 
8
 
C under constant, mild agitation. After this time, the reaction was ter-
minated by dilution with DME/F-12 containing 10% calf serum (GIBCO
BRL), and samples of the microvessels prepared for combined immuno-
histochemical detection of heparan sulfate and binding with biotinylated
chemokines.
 
Statistical Analysis
 
To determine the significance of the effect of heparinase I treatment on
chemokine binding, a one-way ANOVA was performed, followed by a
Bonferroni multiple comparisons test.
 
Results
 
Expression of MCP-1 and MIP-1
 
a
 
 Binding Sites on 
Brain Microvessels
 
To visualize chemokine binding sites, isolated brain mi- 
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crovessels were reacted first with biotinylated MCP-1 or
biotinylated MIP-1
 
a
 
, and subsequently with fluorescein-
avidin (Fig. 1). The pattern of MCP-1 binding appears as a
near continuous sheath encapsulating the length of the
vessel fragment. In comparison, the binding of MIP-1
 
a
 
 ex-
hibits a discontinuous or punctate arrangement along the
microvascular segment. Control experiments, using con-
current exposure of microvessels to labeled chemokines
and antichemokine antibodies, revealed no such staining.
PBM, which express receptors for both MCP-1 and MIP-
1
 
a
 
 (2, 3, 19, 35), also demonstrated binding of both labeled
 
chemokines. No staining of PBM was obtained in the pres-
ence of antichemokine antibodies.
To better visualize the unique topologic distributions of
MCP-1 and MIP-1
 
a
 
 binding sites, confocal images of mi-
crovessels were reconstructed to display both endothelial
cells and chemokine binding in three-dimensional space
(see Figs. 2 and 4). As clearly shown in Fig. 2, the sphere of
MCP-1 binding envelopes the endothelial cells in a rela-
tively smooth and nearly continuous pattern. In striking
contrast, binding of MIP-1
 
a
 
 appears clustered in discrete
patches, periodically decorating the abluminal endothelial
surface in a punctate fashion.
 
Specificity of Chemokine Binding
 
As the binding patterns of biotinylated MCP-1 and bio-
tinylated MIP-1
 
a
 
 were clearly distinguishable, experi-
ments were performed to confirm the presence of sepa-
rate and specific binding sites for these chemokines along
the microvascular surface. Specifically, studies were con-
ducted to determine whether binding of these labeled
chemokines could be antagonized by increasing concen-
trations of unlabeled ligand. Fig. 3 unequivocally indicates
that such competition can be achieved for both MCP-1
and MIP-1
 
a
 
.
 
 Greater than 90% of the binding of both la-
beled chemokines could be inhibited by competition with
100-fold excess of the respective unlabeled chemokines.
Moreover, there was no cross-inhibition between these
two chemokines, i.e., unlabeled MCP-1 did not inhibit the
binding of labeled MIP-1
 
a
 
, or vice versa. Results from these
competition studies further underscore the premise of sep-
arate and specific binding sites for MCP-1 and MIP-1
 
a
 
along the abluminal surface of brain microvessels.
In addition to exhibiting homologous, but not heterolo-
gous, competition, the binding of both labeled chemokines
to perivascular domains was shown to be saturable (Fig.
4), with 
 
K
 
d
 
 values of 
 
z
 
2 nM for MCP-1 and 
 
z
 
0.5 nM for
MIP-1
 
a
 
. Corresponding Hill coefficients were
 
 n 
 
5 
 
6 and
 
n 
 
5 
 
1.1 for MCP-1 and MIP-1
 
a
 
 binding, respectively.
Taken together with the qualitative depictions, these
quantitative data are consistent with the presence of a lim-
ited number of spatially and biochemically distinct, high-
affinity binding sites for MCP-1 and MIP-1
 
a
 
 along the pa-
renchymal face of microvessels from brain.
 
Localization of MCP-1 and MIP-1
 
a
 
 Binding Sites
 
To exclude the possibility that monocyte-derived peri-
vascular macrophages were the source of chemokine bind-
ing sites, double-label fluorescence microscopy was
performed to resolve macrophage and MCP-1/MIP-1
 
a
 
distributions. It can be clearly seen in Fig. 5 that the bind-
ing patterns of both these chemokines and perivascular
macrophages are completely distinguishable. Assessment
of colocalization of chemokine binding with other perivas-
cular cell types, such as pericytes, mast cells, plasma cells,
and smooth muscle cells, which only showed very limited
distribution in these microvessels preparations, addition-
ally revealed drastically dissimilar patterns (data not
shown). Lastly, as several chemokines have demonstrated
affinity for proteoglycans and other extracellular matrix
components (11, 45, 47, 49, 50), we examined whether
Figure 1. MCP-1 and MIP-1a binding to human brain microves-
sels. Microvessels purified from human brain cortex were reacted
with either biotinylated MCP-1 (a) or biotinylated MIP-1a (b),
and then visualized with avidin-fluorescein. Negative controls for
microvascular staining included microvessels coincubated with
MCP-1 (c) or biotinylated MIP-1a (d) and their corresponding,
specific antibodies. Positive controls for detection of chemokine
binding sites show PBM, known to possess receptors for MCP-1
and MIP-1a, reactive with biotinylated MCP-1 (e) and biotiny-
lated MIP-1a (f). Negative controls for PBM staining included
biotinylated MCP-1 (g) and biotinylated MIP-1a (h) along with
their respective antibodies. Bars, 40 mm. 
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MCP-1 and/or MIP-1
 
a
 
 binding coincided with three major
constituents of the subendothelial matrix: heparan sulfate,
collagen type IV, and laminin. Fig. 5 indicates that binding
sites for MCP-1 and MIP-1
 
a
 
 lie predominantly internal to
both heparan sulfate and collagen type IV domains, but
appear intermixed with that of laminin. Thus, it seems un-
likely that binding to brain microvessels occurs principally
via attachment to either collagen type IV or heparan sul-
fate. However, laminin may be associated in limited con-
text with the binding of both these chemokines. This inter-
pretation is consistent with a recent report describing
MCP-1 and MIP-1
 
a
 
 induction of mast cell migration
across microporous filters coated with laminin, but not
with collagen type IV (46).
To further assure that chemokine binding to brain mi-
crovessels did not merely reflect attachment to heparan
sulfate, a glycosaminoglycan (GAG) to which many che-
mokines, including MCP-1 and MIP-1
 
a
 
, have been re-
ported to adhere (17, 25), binding experiments were also
performed on microvessels stripped of heparan sulfate by
treatment with heparinase I. As shown in Fig. 6, such enzy-
matic treatment removed nearly all perivascular heparan
sulfate, as judged by immunofluorescence. Despite this,
neither MCP-1 nor MIP-1
 
a
 
 binding to microvessels was
diminished. On the contrary, slightly heightened binding
of both chemokines was observed (Fig. 7). It was further
observed that microvessel binding of neither chemokine
could be blocked by coincubation with 1,000-fold excess of
Figure 2. Topological distributions of MCP-1
and MIP-1a binding along human brain mi-
crovessels. Microvessels were first reacted with
biotinylated chemokines/avidin-fluorescein, fixed,
then subsequently immunoreacted with mono-
clonal anti–Factor VIII antibody/rhodamine
anti–mouse IgG, to detect endothelial cells.
Samples were viewed by confocal microscopy,
z-series were obtained, and three-dimensional
images were reconstructed as described in Mate-
rials and Methods. MCP-1 (a–d) and MIP-1a
(e–h) staining are indicated in green, and immu-
nostained endothelial cells appear red. Images in
a–d and e–h represent different orientations of a
given microvessel, displaying a nearly 3608 distri-
bution of the binding sites for the two chemo-
kines. Bars, 40 mm. Images in d and h represent
portions of b and e, respectively, that have been
enlarged by computer. 
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either heparin or heparan sulfate (data not shown). Col-
lectively, these data strongly argue against heparan sul-
fate, alone, being responsible for MCP-1 and MIP-1
 
a
 
binding to the abluminal surface of brain microvessels.
Similar experiments to gauge the effects of enzymatic re-
moval of laminin and collagen (using cathepsins B and D,
and collagenase type IV, respectively) also indicated no
significant diminution in the binding of either chemokine
(data not shown).
 
Detection of MCP-1 and MIP-1
 
a
 
 Receptors
 
Insofar as both kinetic and cytological data indicated that
both MCP-1 and MIP-1
 
a
 
 were binding to high-affinity
sites that were closely associated with the endothelium, we
further assessed whether brain microvessels express recep-
tors for these chemokines. These receptors, designated by
the abbreviation CCR, have been well documented in leu-
kocytes, and their sequences cloned (35). CCR2 is consid-
ered the lone, specific receptor for MCP-1, while both CCR1
and CCR5 are the recognized receptors for MIP-1
 
a
 
. As in-
dicated in Fig. 8, brain microvessels display immunoreac-
tivity with specific antibodies to each of these receptors.
All three antibodies were similarly reactive with PBM
(data not shown), consistent with these cells’ ability to
bind both chemokines (as visualized above). However, it is
important to note that microvascular staining with the an-
tireceptor antibodies was not similar to that obtained with
anti-CD68 staining of perivascular macrophages (Fig. 5),
the latter clearly exhibiting immunoreactivity in discrete
cellular domains that lie outside the immediate vascular
wall. In a contrary manner, antireceptor antibodies deco-
rate the contour of microvessels in a more continuous
manner, and apparently bind to sites in close apposition to
the abluminal endothelial surface. Thus, antichemokine
receptor staining of microvessels may include, but is not
restricted to, perivascular macrophages.
 
Discussion
 
Specific binding of MCP-1 and MIP-1
 
a
 
 to separate do-
Figure 3. Competition of MCP-1 and MIP-1a binding to brain
microvessels. Microvessels were incubated with a constant con-
centration of either biotinylated MCP-1 or biotinylated MIP-1a
in the presence of increasing concentrations of unlabeled chemo-
kine (indicated as x-fold greater than biotinylated chemokine).
Relative chemokine binding was determined, and corrected for
nonspecific binding as described in Materials and Methods. Val-
ues are plotted as percentages of maximal binding obtained in
the absence of unlabeled competitor 6 standard error. (a) Bio-
tinylated MCP-1 plus unlabeled MCP-1; (b) biotinylated MCP-1
plus unlabeled MIP-1a; (c) biotinylated MIP-1a plus unlabeled
MIP-1a; and (d) biotinylated MIP-1a plus unlabeled MCP-1.
Figure 4. Saturable binding of MCP-1 and MIP-1a along brain
microvessels. Total labeled chemokine binding at increasing bi-
otinylated chemokine concentrations was assessed as described
in Materials and Methods. Nonspecific binding was similarly de-
termined in the presence of 50-fold excess of unlabeled chemo-
kine, and subtracted from total binding values to give specific
binding (mean pixel intensity). 
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Figure 5. Codistribution of MCP-1
and MIP-1a binding with peri-
vascular markers along brain
microvessels. Microvessels were
incubated with biotinylated chemo-
kines (either MCP-1, left column,
or MCP-1a, right column) and the
indicated antibodies (top to bot-
tom). Chemokine binding is dis-
played in green, and antibody
reactions are in red. Insets show
three-dimensional reconstruc-
tions, obtained as described in Ma-
terials and Methods. For orienta-
tion purposes, asterisks indicate
the direction looking into the
lumen of each microvessel frag-
ment. Anti-CD68 specifically
stains monocyte-derived macro-
phages. Arrowheads denote stain-
ing of the individual matrix com-
ponents, which appear outside the
domains of chemokine binding.
Bars, 40 mm. 
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mains along the microvessel outer surface was determined
according to the following criteria. First, the distribution
patterns of MCP-1 and MIP-1
 
a
 
 binding were remarkably
different from each other. Second, binding of labeled
MCP-1 and MIP-1
 
a
 
 could each be inhibited nearly 95% by
100-fold excess of their unlabeled homologues, but not by
unlabeled derivatives of the other chemokine. Third, bind-
ing of both chemokines was saturable. Finally, neither
MCP-1 nor MIP-1
 
a
 
 binding was observed to colocalize
with three major components of the basement membrane
or to be quantitatively dependent upon the presence of
these constituents, implying a lack of any significant
chemokine trapping within the subendothelial matrix.
It is important to reemphasize that the chemokine bind-
ing sites visualized and characterized here reside strictly
on the abluminal surface of the microvessels. These results
are thus to be distinguished from descriptions of radiola-
beled chemokine binding to the apical surface of cultured
endothelial cells, which represents the luminal microvas-
cular surface in situ. In the latter case, chemokine binding
has been demonstrated to be largely dependent upon the
presence of GAGs (17, 40, 41). Attachment of chemokines
to such GAGs is thought to serve the passive role of se-
questering chemokines in the luminal space, raising their
effective concentration and, thus, their probability of en-
countering a chemokine receptor on a loosely tethered
leukocyte (17). In contrast to that observed in these previ-
ous reports, MCP-1 and MIP-1a binding to isolated brain
microvessels was not diminished as a result of enzymatic
removal of perivascular heparan sulfate, a prominent
chemokine-binding GAG. As similar heparinase treat-
ment to that performed here has been shown to com-
pletely antagonize the binding of numerous chemokines to
both cultured cells and isolated subendothelial matrix (11,
25), our findings infer that, at the very least, attachment to
heparan sulfate is not the sole mechanism underlying
MCP-1 and MIP-1a binding to human brain microvessels.
Of course, these chemokines might interact with GAGs
other than heparan sulfate present along the abluminal
surface of brain microvessels, and do so with varying affin-
ities (49). However, the Kd values obtained here (#2.0 nM)
are significantly lower than those generally reported for
chemokine attachment to various GAGs, e.g., mid-nano-
molar to low millimolar range (27). That enzymatic re-
moval of both laminin and collagen was additionally un-
able to lessen the degree of MCP-1 and MIP-1a binding
sustains the concept that these perivascular chemokine
binding domains are more closely associated with integral
elements of the brain microvasculature than with compo-
nents of the subendothelial matrix. The additional lack of
coincidence between chemokine binding and the presence
of perivascular cells also eliminates these cells as being the
major target of chemokine binding.
What then might be the nature of these abluminal
chemokine binding sites? MCP-1 and MIP-1a binding may
reflect attachment to specific chemokine receptors on the
surface of endothelial cells. In this regard, the fluorescence
Figure 6. Heparinase I treatment of human brain microvessels.
Freshly isolated brain microvessels were exposed to heparinase I
treatment and then subjected to biotinylated chemokine binding
(MCP-1 and MIP-1a) and immunofluorescent detection of hepa-
ran sulfate as described in Materials and Methods. Green fluores-
cence indicates chemokine binding and red fluorescence indi-
cates heparan sulfate distribution. Boxed areas at the top right
are three-dimensional renderings of optical cross sections
through individual microvessels, looking into the vessel lumen
(denoted by asterisks). (a and b) Chemokine binding to control
microvessels not treated with enzyme; (c and d) chemokine bind-
ing to heparinase I–treated samples. Despite nearly complete re-
moval of perivascular heparan sulfate by pretreatment of mi-
crovessels with heparinase I, binding of both MCP-1 and MIP-1a
is still readily detected. Bars, 40 mm.
Figure 7. Chemokine binding to heparinase I–treated human
brain microvessels. Brain microvessels were treated as described
in Fig. 5, and quantitatively evaluated for their extent of chemo-
kine binding 6 standard error (as detailed in Materials and
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competition assays described here mirror those reported
for chemokine binding to cloned CCR1 and CCR2 recep-
tors (31, 32), in that 100-fold excess of unlabeled ligand ab-
rogated nearly 95% of labeled chemokine binding. That
we were further able to detect immunostaining with anti-
bodies to CCR1, CCR2, and CCR5 is yet additional sup-
port. Lastly, the estimated Kd values for both MCP-1 and
MIP-1a binding to brain microvessels are within the low
nanomolar range generally reported for these chemo-
kines’ binding to their respective receptors (reviewed in
27, 43). The relatively high degree of apparent cooperativity
in MCP-1 binding, as indicated by a Hill coefficient of n 5
6, may reflect cooperative interactions between high-affin-
ity chemokine receptors and low-affinity extracellular ma-
trix component(s) (17). Thus, our observations could be
the first evidence of expression of receptors for MCP-1
and MIP-1a on, or around, the abluminal surface of mi-
crovascular endothelium. In agreement with this conten-
tion, recent studies have indicated both expression and ac-
tivity of chemokine receptors on cultured endothelial cells
(7, 8, 15), although no cytological distributions of these re-
ceptors were described.
Aside from binding to specific receptors on brain mi-
crovessels, MCP-1 and MIP-1a may also be engaging the
Duffy antigen receptor for chemokines (DARC), a pro-
miscuous receptor that binds several chemokines (24) and
is expressed in endothelial cells (33). Consistent with this
possibility, Horuk et al. (18) demonstrated immunocy-
tochemical staining of capillaries and postcapillary venules
of human brain sections with an antibody to DARC. How-
ever, considering the different binding patterns for MCP-1
and MIP-1a reported here, and the noted lack of affinity
of MIP-1a for DARC (24), binding to DARC cannot be
the exclusive means by which both these chemokines asso-
ciate with brain microvessels.
What could be the functional significance of these
perivascular chemokine binding domains? Middleton et al.
(29) presented evidence that another chemokine, interleu-
kin 8, is transcytosed from the abluminal to the luminal
microvascular surface in skin, where it appears to reside
on the tips of endothelial microvilli. Such luminal “presen-
tation” of bound chemokines is thought to provide the
proper context for efficient activation of leukocyte b-inte-
grins (2, 6, 44, 45). The binding sites described here might
represent domains to which the MCP-1 and MIP-1a ini-
tially dock, before transcytosis across the microvascular
endothelium of brain. MCP-1 and MIP-1a binding to brain
microvessels may additionally signal vascular permeability
changes through cytoskeletal reorganization, as has been
suggested most recently for interleukin 8 (9). Further-
more, binding to these abluminal sites may function to
prevent these chemokines from being diluted within the
perivascular space and, thus, augment the intensity, pro-
long the duration, and/or influence the site of inflamma-
tory reactions (11). While all these possibilities remain a
priori, the pleiotropic nature of chemokines (30, 43) is
consistent with these binding sites subserving several func-
tions.
Are these perivascular chemokine binding sites re-
stricted to, or enriched in, microvessels from brain? While
this remains to be explored, the stringent requirements for
maintaining an effective blood-brain barrier dictates that
specialized mechanisms, possibly receptors, exist within
brain microvessels for the purpose of efficiently communi-
cating chemokine signals. In contrast, less restrictive vas-
cular beds may simply allow tissue-derived chemokines to
percolate through leaky endothelial junctions into the vas-
cular lumen. That Randolph and Furie were not able to
demonstrate significant binding of MCP-1, when this
chemokine was applied to the basolateral (abluminal) sur-
face of cultured monolayers of human umbilical vein en-
dothelial cells (36), may, in part, reflect this phenotypic di-
versity. It may also be that specific endothelial chemokine
binding sites are rapidly lost, or their membrane polarity
altered, upon adaptation to culture conditions (39).
As the myriad of chemokine functions begins to resolve,
Figure 8. Chemokine receptor expres-
sion in human brain microvessels.
Brain microvessels were immuno-
stained with anti-CCR1, anti-CCR2,
anti-CCR5, and isotype control anti-
body (IC), all followed by fluorescein-
conjugated secondary antibody, or with
just secondary antibody alone as a neg-
ative control (NC). Bars, 80 mm.Andjelkovic et al. Chemokine Binding on Brain Microvessels 411
so will their pathogenic role(s) in disease become more ap-
preciated. In turn, this will lead to greater efforts to specif-
ically antagonize chemokine action at sites of inflam-
mation and infection. Heightened understanding of the
interactions of chemokines with their binding sites on the
vascular surface will be a significant step in this direction.
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